FindTrial
Sign In

CD4 Antigens

DRUG5 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Genentech, Inc.

Conditions

HIV Infections

Phase 1

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex
CompletedNCT00002004
Genentech, Inc.HIV Infections
Updated: 2005-06-24
An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive
CompletedNCT00000721
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1991-03-31Target: 85Updated: 2021-10-28
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection
CompletedNCT00000984
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Target: 40Updated: 2005-06-24

Phase 2

A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)
TerminatedNCT00000659
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Target: 80Updated: 2011-03-14

Unknown Phase

A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex
CompletedNCT00002005
Genentech, Inc.HIV Infections
Updated: 2005-06-24